Table 1

Characteristics of patients with CAD and type 2 diabetes, IGT, IFG, or NG

VariableType 2 diabetes (n = 834)IGT (n = 314)IFG (n = 103)NG (n = 695)
Age (years)67 (8)69 (8)*66 (8)66 (9)
Men, n (%)577 (69)193 (62)*71 (69)486 (70)
BMI (kg/m2)30.0 (4.9)*27.5 (4.2)*28.4 (3.9)*26.6 (3.6)
Waist-to-hip ratio0.99 (0.08)*0.95 (0.09)0.96 (0.07)0.94 (0.09)
Resting heart rate (bpm)64 (11)*62 (10)*61 (11)58 (9)
Blood pressure at rest (mmHg)
 Systolic147 (23)148 (25)142 (23)144 (23)
 Diastolic78 (11)*76 (11)76 (10)77 (10)
Smoking status, n (%)
 Current smoker74 (9)20 (6)11 (11)62 (9)
 Ex-smoker387 (47)122 (39)38 (37)286 (41)
History of myocardial infarction, n (%)383 (46)159 (51)57 (55)330 (48)
 NSTEMI262 (32)97 (31)43 (42)212 (31)
 STEMI139 (17)65 (21)19 (19)131 (19)
No history of revascularization, n (%)172 (20)69 (22)18 (18)141 (20)
PCI, n (%)453 (54)173 (55)58 (56)416 (60)
CABG, n (%)209 (25)71 (23)27 (26)138 (20)
CCS class ≥2, n (%)414 (50)*154 (49)*40 (39)231 (33)
Syntax Score2 (0–6)*0 (0–4)0 (0–5)0 (0–5)
Duration of type 2 diabetes (years)5 (2–12)NANANA
Echocardiography
 LV ejection fraction (%)63 (10)65 (9)64 (9)64 (8)
 LV mass index (g/m2)110 (28)*107 (31)103 (24)106 (25)
Medication, n (%)
 β-Blockers757 (91)*280 (89)89 (86)579 (84)
 ACE inhibitors or angiotensin receptor blockers645 (77)*214 (68)*59 (57)413 (59)
 Calcium channel blockers273 (33)*72 (23)16 (16)114 (16)
 Diuretics406 (49)*87 (28)25 (24)149 (21)
 Statins758 (91)291 (93)94 (91)635 (91)
 Oral diabetes medications617 (74)NANANA
 Insulin215 (26)NANANA
 Oral diabetes medication + insulin153 (18)NANANA
Laboratory analyses
 HbA1c (mmol/mol)53 (13)*42 (5)*41 (4)40 (4)
 HbA1c (%)7.0 (1.2)*6.0 (0.5)*5.9 (0.4)5.8 (0.4)
 Fasting glucose (mmol/L)7.6 (2.2)*5.9 (0.6)*6.5 (0.3)*5.4 (0.4)
 2-h postload glucose (mmol/L)13.0 (2.0)*§10.3 (0.9)*7.4 (1.1)7.1 (1.1)
 Total cholesterol (mmol/L)3.89 (0.86)*4.03 (0.94)4.24 (0.92)4.05 (0.85)
 HDL cholesterol (mmol/L)1.18 (0.29)*1.30 (0.32)1.29 (0.27)1.35 (0.33)
 LDL cholesterol (mmol/L)2.22 (0.74)*2.33 (0.80)2.48 (0.88)2.32 (0.77)
 Triglycerides (mmol/L)1.40 (1.04–1.92)*1.19 (0.89–1.59)*1.29 (0.90–1.59)*1.06 (0.82–1.40)
 Creatinine clearance (mL/min)101 (40)*84 (29)97 (30)89 (28)
 Urinary albumin-to-creatinine ratio1.0 (0.7–2.0)*0.8 (0.5–1.2)0.7 (0.5–1.0)0.8 (0.5–1.1)
End points, n (%)
 Death127 (15.2)*34 (10.8)*5 (4.9)42 (6.0)
 Cardiac death68 (8.2)*12 (3.8)3 (2.9)18 (2.6)
 Hospitalization due to ACS (5-year follow-up, n = 1,698)132 (18.1)35 (13.3)13 (14.6)89 (14.5)
 Hospitalization due to CHF (5-year follow-up, n = 1,676)53 (7.4)*8 (3.1)2 (2.3)15 (2.5)
 MACE212 (25.4)*48 (15.3)14 (13.6)111 (16.0)
 New type 2 diabetes (5-year follow-up, n = 798; IGF/IGT and NG at entry)NA25 (11.2)*9 (12.2)*18 (3.6)
  • Values are mean (SD) or median (first–third quartile) unless otherwise indicated. CABG, coronary artery bypass grafting; NA, not applicable; NSTEMI, non–ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction.

  • *P < 0.05 vs. NG.

  • P < 0.05 vs. IFG.

  • P < 0.05 vs. IGT.

  • §n = 100.

  • ‖Includes aborted cardiac arrests.